Payment overview · 2025
General Payments
$2,742.86
150 reported records · 21 companies
Healthcare provider profile · identity verified
Rena Khanukayeva
Allopathic & Osteopathic Physicians|Family Medicine · STATEN ISLAND, NY · NPI 1255358164
Verified facts
What the public records show
CMS Open Payments records show Rena Khanukayeva received $2,742.86 in general payments during 2025 across 150 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Ibsrela, Jardiance, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Prolia, Qulipta, Rybelsus, Trelegy Ellipta, Ubrelvy, Xifaxan, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 852 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 604 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Prolia by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ibsrela by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 481 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EUCRISA as an associated drug or biological on 1712 records involving 991 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eucrisa by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xifaxan by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $473.24 | 17.2% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $451.99 | 16.5% | 33 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $351.25 | 12.8% | 26 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $201.05 | 7.3% | 10 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $165.07 | 6.0% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $136.13 | 5.0% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $122.50 | 4.5% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $121.89 | 4.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.85 | 4.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.79 | 4.1% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $95.72 | 3.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.45 | 2.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.59 | 2.1% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $51.09 | 1.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.34 | 1.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.88 | 1.6% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.86 | 1.4% | 2 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.82 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.79 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.52 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.04 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,742.86 | 150 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $351.25 | 26 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $278.35 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $237.93 | 23 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $222.23 | 22 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $165.07 | 6 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $156.80 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.94 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $136.13 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $133.94 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.94 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $122.50 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $121.89 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $111.79 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $95.72 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.00 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.95 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.45 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.59 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $51.09 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $51.09 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $51.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.99 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $44.25 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.85 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.85 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 271 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 319 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 269 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 199 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 852 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 276 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 228 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 90 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 56 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 103 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 135 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 604 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 146 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
271 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
852 | 119 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
271 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
135 | 20 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
604 | 82 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
90 | 53 |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
481 | 62 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
269 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
276 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
228 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
319 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | EUCRISA open payments reported associated product |
CMS Open Payments — General Payments 1712 supporting records · 991 recipient NPIs · example record 1228794851 |
Eucrisa · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
146 | 25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1118 | 182 |
| Vascepa | Icosapent Ethyl | 1080 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 924 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 855 | 143 |
| Linzess | Linaclotide | 852 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 849 | 127 |
| Diclofenac Sodium | Diclofenac Sodium | 782 | 132 |
| Metformin Hcl | Metformin Hcl | 761 | 126 |
| Losartan Potassium | Losartan Potassium | 613 | 107 |
| Zenpep | Lipase/Protease/Amylase | 604 | 82 |
| Clonidine Hcl | Clonidine Hcl | 575 | 103 |
| Gabapentin | Gabapentin | 518 | 109 |
| Omeprazole | Omeprazole | 484 | 87 |
| Myrbetriq | Mirabegron | 481 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 59 |
| Dexlansoprazole Dr | Dexlansoprazole | 391 | 62 |
| Celecoxib | Celecoxib | 370 | 68 |
| Icosapent Ethyl | Icosapent Ethyl | 352 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 62 |
| Carvedilol | Carvedilol | 328 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 46 |
| Eliquis | Apixaban | 319 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 313 | 90 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 308 | 60 |
| Dexilant | Dexlansoprazole | 301 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 288 | 36 |
| Mounjaro | Tirzepatide | 276 | 48 |
| Creon | Lipase/Protease/Amylase | 271 | 55 |
| Repaglinide | Repaglinide | 271 | 37 |
| Synthroid | Levothyroxine Sodium | 271 | 30 |
| Farxiga | Dapagliflozin Propanediol | 269 | 42 |
| Famotidine | Famotidine | 264 | 53 |
| Alendronate Sodium | Alendronate Sodium | 257 | 44 |
| Memantine Hcl Er | Memantine Hcl | 256 | 34 |
| Furosemide | Furosemide | 248 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 244 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 59 |
| Ezetimibe | Ezetimibe | 243 | 45 |
| Ozempic | Semaglutide | 228 | 42 |
| Montelukast Sodium | Montelukast Sodium | 224 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 41 |
| Meloxicam | Meloxicam | 207 | 59 |
| Januvia | Sitagliptin Phosphate | 206 | 36 |
| Breo Ellipta | Fluticasone/Vilanterol | 205 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 205 | 37 |
| Simvastatin | Simvastatin | 204 | 38 |
| Restasis | Cyclosporine | 203 | 34 |
| Allopurinol | Allopurinol | 199 | 32 |
| Jardiance | Empagliflozin | 199 | 28 |
| Meclizine Hcl | Meclizine Hcl | 197 | 43 |
| Valsartan | Valsartan | 193 | 34 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 191 | 23 |
| Azithromycin | Azithromycin | 189 | 145 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 187 | 36 |
| Mupirocin | Mupirocin | 179 | 61 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 175 | 29 |
| Tradjenta | Linagliptin | 174 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 38 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 164 | 44 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 164 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 31 |
| Donepezil Hcl | Donepezil Hcl | 159 | 27 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 155 | 33 |
| Pregabalin | Pregabalin | 149 | 22 |
| Ztlido | Lidocaine | 146 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 139 | 33 |
| Ubrelvy | Ubrogepant | 135 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 133 | 28 |
| Halobetasol Propionate | Halobetasol Propionate | 133 | 44 |
| Ranolazine Er | Ranolazine | 132 | 19 |
| Repatha Sureclick | Evolocumab | 129 | 20 |
| Mirtazapine | Mirtazapine | 128 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 124 | 44 |
| Ammonium Lactate | Ammonium Lactate | 121 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 19 |
| Memantine Hcl | Memantine Hcl | 115 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 114 | 22 |
| Lisinopril | Lisinopril | 114 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 114 | 21 |
| Enalapril Maleate | Enalapril Maleate | 109 | 24 |
| Nitroglycerin | Nitroglycerin | 104 | 28 |
| Edarbi | Azilsartan Medoxomil | 103 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 17 |
| Horizant | Gabapentin Enacarbil | 101 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 17 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 98 | 12 |
| Ibuprofen | Ibuprofen | 98 | 33 |
| Torsemide | Torsemide | 97 | 15 |
| Atenolol | Atenolol | 95 | 21 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 93 | 25 |
| Dutasteride | Dutasteride | 90 | 13 |
| Prolia | Denosumab | 90 | 53 |
| Ventolin Hfa | Albuterol Sulfate | 90 | 17 |
| Colchicine | Colchicine | 89 | 19 |
| Lidocaine | Lidocaine | 89 | 22 |
| Entresto | Sacubitril/Valsartan | 88 | 12 |
| Levofloxacin | Levofloxacin | 87 | 70 |
| Xarelto | Rivaroxaban | 86 | 11 |
| Fenofibrate | Fenofibrate | 84 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 27 |
| Ketoconazole | Ketoconazole | 83 | 16 |
| Clotrimazole | Clotrimazole | 77 | 21 |
| Cyclosporine | Cyclosporine | 76 | 13 |
| Glimepiride | Glimepiride | 76 | 14 |
| Azelastine Hcl | Azelastine Hcl | 75 | 25 |
| Clonazepam | Clonazepam | 74 | 29 |
| Finasteride | Finasteride | 74 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 73 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 54 |
| Glipizide Er | Glipizide | 72 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 71 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 14 |
| Nifedipine Er | Nifedipine | 71 | 15 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 68 | 15 |
| Procto-Med Hc | Hydrocortisone | 68 | 19 |
| Valacyclovir | Valacyclovir Hcl | 68 | 31 |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 66 | 11 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 64 | 11 |
| Trulance | Plecanatide | 64 | 16 |
| Benicar | Olmesartan Medoxomil | 62 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 62 | 14 |
| Loperamide | Loperamide Hcl | 62 | 17 |
| Fenofibrate | Fenofibrate,micronized | 61 | suppressed |
| Methylprednisolone | Methylprednisolone | 61 | 36 |
| Nexium | Esomeprazole Magnesium | 61 | suppressed |
| Spironolactone | Spironolactone | 61 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 61 | suppressed |
| Crestor | Rosuvastatin Calcium | 60 | suppressed |
| Licart | Diclofenac Epolamine | 60 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | 14 |
| Diclofenac Epolamine | Diclofenac Epolamine | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | 22 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 56 | suppressed |
| Hydrocortisone | Hydrocortisone | 56 | 26 |
| Qulipta | Atogepant | 56 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 37 |
| Clonidine | Clonidine | 54 | suppressed |
| Nystatin | Nystatin | 53 | 16 |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 51 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Ofloxacin | Ofloxacin | 51 | 35 |
| Sertraline Hcl | Sertraline Hcl | 51 | suppressed |
| Lactulose | Lactulose | 49 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Glipizide | Glipizide | 48 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 48 | suppressed |
| Proctozone-Hc | Hydrocortisone | 48 | 13 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 48 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 14 |
| Single Use Swab | Alcohol Antiseptic Pads | 47 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Lofena | Diclofenac Potassium | 43 | suppressed |
| Prednisone | Prednisone | 43 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 43 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 42 | suppressed |
| Xiidra | Lifitegrast | 40 | 13 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 39 | suppressed |
| Eucrisa | Crisaborole | 39 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 35 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 33 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Felodipine Er | Felodipine | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Gemtesa | Vibegron | 30 | suppressed |
| Metronidazole | Metronidazole | 29 | 19 |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Calcipotriene | Calcipotriene | 28 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 25 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | 11 |
| Metformin Er Osmotic | Metformin Hcl | 24 | suppressed |
| Nexletol | Bempedoic Acid | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 21 | 11 |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Latuda | Lurasidone Hcl | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Daliresp | Roflumilast | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Bystolic | Nebivolol Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Terconazole | Terconazole | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Canasa | Mesalamine | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Ibsrela | Tenapanor Hcl | 16 | suppressed |
| Jublia | Efinaconazole | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Nicotrol Ns | Nicotine | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Zetia | Ezetimibe | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Diovan | Valsartan | 15 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Desipramine Hcl | Desipramine Hcl | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Toviaz | Fesoterodine Fumarate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Ery | Erythromycin Base In Ethanol | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Xhance | Fluticasone Propionate | 12 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,742.86 · 150 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, CREON, ELIQUIS, ELYXYB - CELECOXIB, EVENITY, FARXIGA, GLYCATE, IBSRELA, JARDIANCE, KRISTALOSE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PROLIA, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VPRIV, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 30 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error